Immunotherapeutic targets in non-small cell lung cancer |
| |
| Authors: | Habib Sadeghirad Tayyeb Bahrami Sepideh M. Layeghi Hassan Yousefi Meysam Rezaei Seyed R. Hosseini-Fard Payar Radfar Majid E. Warkiani Ken O'Byrne Arutha Kulasinghe |
| |
| Affiliation: | 1. University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia;2. Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran;3. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;4. Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, Louisiana, USA;5. School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia;6. Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia |
| |
| Abstract: | ![]()
Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy. |
| |
| Keywords: | immunotherapy non-small cell lung cancer NSCLC TME tumour microenvironment |
|
|
